Intended for healthcare professionals

Rapid response to:

News

Pressure grows on Lancet to review “flawed” PACE trial

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3621 (Published 22 August 2018) Cite this as: BMJ 2018;362:k3621

Rapid Response:

Re: Pressure grows on Lancet to review “flawed” PACE trial

Another aspect that may be behind a smoke screen is that of fully informed consent. Presumably the participants in the PACE trial gave this prior to participation. But if the parameters for recovery and/or improvement were changed after the data was collected, wouldn’t this render previous informed consent null and void and, therefore, negate the trial results a priori?

Competing interests: No competing interests

23 August 2018
Polly J Moyer
Patient advocate
Bristol, UK